SCYNEXIS Company Description

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States.

The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.

It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections.

The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.

SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS, Inc.

Country	United States
Founded	1999
Industry	Biological Products, Except Diagnostic Substances
Employees	18
CEO	David Angulo

Contact Details

Address: 1 Evertrust Plaza Jersey City, New Jersey 07302-6548 United States
Phone	201 884 5485
Website	scynexis.com

Stock Details

Ticker Symbol	0L49
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US8112922005
SIC Code	2836

Key Executives

Name	Position
Dr. David Gonzalez Angulo M.D.	Chief Executive Officer, President and Director
Ivor Macleod CPA, M.B.A.	Chief Financial Officer
Scott Sukenick J.D.	Chief Legal Officer and Corporate Secretary
Daniella Gigante	Vice President of Human Resources and Information Technology